Our technology on using cfDNA methylome to detect cancer has been published in Nature Communications!
News link: [UCLA News] [GenomeWeb] [HemOnc Today] [ScieneDaily] [Biocompare]
EarlyDx has been awarded a NIH SBIR Phase II grant on validating our cfDNA methylome technology for the early detection of liver and lung cancer.
EarlyDx announced the appointment of Guanghui Hu as co-CEO.
EarlyDx published cfTrack: Non-invasive monitoring of cancer MRD, Recurrence, and Evolution in Clinical Cancer Research.
EarlyDx Awarded an NIH SBIR Phase I Contract on the Further Development of the Cloud Computing Platform for Liquid Biopsy.
Co-founder Jasmine Zhou presented EarlyDx’s CancerRadar Technology and Clinical Data in Oral Presentation at AACR Annual Meeting 2021 on April 10, 2021.
EarlyDx Awarded an NIH SBIR Phase I Grant for Assay Development.
EarlyDx closed $5M Series Seed-1 Fundraising Led by Alpha Edison.
EarlyDx Exhibits its One-Stop Shop Bioinformatics Platform, EarlyDx-Cloud, at 2019 ASCO Annual Meeting.